Buy LL-37 (CAP-18) Peptide

LL-37 (Cap-18) peptide is a naturally occurring antimicrobial peptide vital for the immune system’s defense against pathogens. It exhibits strong antibacterial, antiviral, and antifungal properties, helping to neutralize harmful microbes and reduce inflammation. Additionally, LL-37 has an important role in therapeutic applications in wound healing, skin infections, and modulating immune responses in various inflammatory diseases.

Sale!
LL-37 Thymosin Alpha-1 Peptide Stack
Original price was: £95.00.Current price is: £85.50. Add to basket
Sale!
LL-37 (Cap-18) Pre-Mixed Pen 5mg
£40.37 – £109.00 Select options This product has multiple variants. The options may be chosen on the product page
LL-37 (Cap-18) Peptide Vial 5mg
£37.79 – £46.77 Select options This product has multiple variants. The options may be chosen on the product page
LL-37 (Cap-18) Nasal Spray
£45.84 – £86.68 Select options This product has multiple variants. The options may be chosen on the product page

LL-37 (CAP-18) Products:

PharmaGrade Store New Zealand supplies multiple LL-37 (CAP-18) Peptide products for clinical research purposes:

- LL-37 (CAP18) Peptide Vial – Lyophilized LL-37, packaged in a glass vial for intramuscular injection into the muscles of study participants. Please note you also require bacteriostatic water to reconstitute the peptide.
  Available in 5mg peptide vials.
- LL-37 CAP18 Nasal Spray – a ready-mixed peptide solution ready for administration into the nasal cavity of clinical research subjects. Choose from 15ml or 30ml nasal sprays here.
- LL-37 CAP18 Pre-Mixed Peptide Pen – LL-37 peptide pen kits and cartridges come ready to use pre-mixed with LL-37 CAP18 peptide and bacteriostatic water. Buy LL-37 5mg Pre-Mixed Pen here.

Buy LL-37 for Research Purposes

LL-37, derived from the human cathelicidin antimicrobial peptide (CAP-18), is a versatile, cationic antimicrobial peptide critical for innate immunity. In New Zealand studies this 37-amino-acid peptide, expressed in various tissues, is primarily released by neutrophils and epithelial cells in response to infections [1].

Its structure includes an amphipathic α-helix, enabling both hydrophilic and hydrophobic interactions. LL-37 shows remarkable stability and bioactivity in diverse environments, making it a vital component of the immune defence system [2].

The peptide’s mechanism of action hinges on its ability to disrupt bacterial cell membranes. By binding to negatively charged phospholipids on microbial membranes, LL-37 integrates itself, causing membrane destabilization, pore formation, or complete lysis [3].

Beyond antimicrobial activity, LL-37 modulates the immune response by recruiting immune cells, promoting wound healing, and neutralizing endotoxins [4]. Its dual role as an antimicrobial agent and immune response regulator underpins its therapeutic potential, particularly in combating antibiotic-resistant bacterial infections and enhancing host defence.

Potential Benefits of LL-37

New Zealand Clinical studies have found that LL-37 (CAP-18), with further research, may have the following benefits and applications

Antimicrobial properties: Effectively combats a wide range of bacteria, fungi, and viruses by disrupting their cell membranes [1].
Immune response regulation: Modulates the innate immune system by recruiting immune cells and reducing excessive inflammation [2].
Wound healing: Stimulates tissue regeneration, angiogenesis, and re-epithelialization, accelerating the wound healing process [5].
Anti-biofilm activity: Prevents and disrupts microbial biofilm formation, reducing bacterial resistance in chronic infections [2].
Neutralization of endotoxins: Binds and neutralizes harmful bacterial toxins, minimizing their inflammatory effects [6].
Cancer therapy: Demonstrates selective cytotoxicity against certain cancer cells, opening pathways for potential anti-cancer treatments [7].
Dermatological applications: Helps manage skin conditions like eczema and psoriasis due to its protective and healing effects [8].
Respiratory health: May assist in reducing inflammation and infection in respiratory diseases such as COPD and asthma [9].
Sepsis management: Counteracts sepsis by neutralizing endotoxins and mitigating inflammation [10].

Clinical Research on LL-37 New Zealand

New Zealand Clinical studies on LL-37 peptide reveal its promising therapeutic potential, showcasing clinical efficacy and safety in various applications. Notable findings highlight its effectiveness in treating infections, including those caused by antibiotic-resistant pathogens, through its potent antimicrobial action [1].

New Zealand Trials demonstrate enhanced wound healing, with improved healing rates and reduced infection severity. LL-37’s ability to modulate immune responses, reduce inflammation, and promote tissue repair has been evident in managing chronic wounds and immune-related conditions.

New Zealand Studies also report its safety profile, with minimal adverse effects in clinical settings. These findings solidify LL-37’s role as a multifunctional therapeutic agent in modern medicine.

LL-37 (CAP-18) Specifications:

View PharmaGrade Store New Zealand LL-37 HPLC Certificate here.

Amino Acid Sequence: Leu Leu Gly Asp-Phe-Phe Arg Lys-Ser Lys-Glu Lys.11e-Gly Lys Glu Phe Lys-Arg Ile Val-Gln Are Ile-Lys Asp Phe Leu Arg Asn Leu Val Pro-Arg Thr-Glu-Ser

Molecular Formula:C205H340N60O53

Molecular Weight: 4493.342 g/mol

Buy LL-37 (CAP-18) New Zealand Peptide online from PharmaGrade.Store today!

LL-37 (CAP-18) & Thymosin Alpha-1 Peptide Stack

New Zealand Research professionals have suggested that combining LL-37 and Thymosin Alpha-1 peptides offers synergistic effects, enhancing immune response, antimicrobial activity, and wound healing.

LL-37’s antimicrobial and tissue-repair properties complement Thymosin Alpha-1’s ability to boost T-cell function and regulate immune responses. Together, they can improve treatment outcomes for infections, including antibiotic-resistant strains, by effectively targeting pathogens while reducing excessive inflammation.

This combination may accelerate healing rates and enhance recovery in immune-related conditions. Clinically, their use might increase therapeutic efficacy and shorten treatment duration, offering a powerful approach for managing chronic infections and complex wounds. Their combined action holds great promise in advancing modern therapeutic applications.

Buy LL-37 Thymosin Alpha-1 New Zealand Peptide Stack

Frequently Asked Questions about LL-37 (CAP-18) New Zealand

What is a Lyophilized peptide?

A lyophilized peptide is a peptide that has been freeze-dried into a powder form. This process, known as lyophilization, involves removing water from the peptide to stabilize it and maintain its structural integrity and activity. Lyophilized peptides can be stored at low temperatures, such as -20 °C, with minimal degradation, making them suitable for long-term preservation, maintaining life span and integrity.

Can LL-37 improve immunity?

LL-37, a human cathelicidin peptide, plays a significant role in the immune system by modulating immune and inflammatory pathways. It is known for its antimicrobial properties, helping to resist various pathogens. LL-37 not only kills microbes but also influences inflammation, which can be beneficial in managing immune responses. Additionally, it has been noted for its potential activity against viruses like SARS-CoV-2, highlighting its broad immunomodulatory effects.

What is host defense?

Host defense refers to the mechanisms and processes that an organism uses to protect itself from pathogens, such as bacteria, viruses, fungi, and parasites. These defenses are part of the immune system and can be broadly categorized into two types: innate and adaptive immunity.

Innate Immunity: This is the first line of defense and includes physical barriers like skin and mucous membranes, as well as immune cells like macrophages and neutrophils that can quickly respond to invaders. It is non-specific and acts immediately or within hours of an antigen’s appearance in the body.
Adaptive Immunity: This is a more specialized and targeted response that develops over time. It involves lymphocytes such as T cells and B cells, which recognize specific antigens and create a memory of them, providing long-lasting protection.

Host defense mechanisms also include antimicrobial peptides like LL-37, which directly kill pathogens and modulate immune responses. These systems work together to detect, neutralize, and eliminate harmful invaders, maintaining the organism’s health.

Blogs:

The Top Pain Relieving Peptides

Explore the potential of pain-relieving peptides as a promising advancement in pain management. The blog highlights how these peptides interact with the body’s natural pain pathways, offering targeted relief with fewer side effects compared to traditional painkillers.

The article discusses various peptides like Melanotan II, ARA-290, and endomorphin analogues, detailing their mechanisms in modulating pain signals and reducing inflammation. It emphasizes the potential benefits of these peptides in managing both acute and chronic pain, while also acknowledging the need for further research to fully understand their long-term safety and efficacy.

Discover pain relieving peptides

Thymosin Alpha-1 and LL-37 peptides on the Immune System

This blog discusses the benefits of Thymosin Alpha-1 and LL-37 peptides, focusing on their impact on the immune system. Thymosin Alpha-1 enhances T-cell function and cytokine production, making it useful in treating conditions like HIV/AIDS and certain cancers. LL-37 offers antimicrobial and immunomodulatory effects, aiding in wound healing and protection against pathogens.

The combination of these peptides can regulate immune responses, potentially benefiting autoimmune disorders and cancer treatment by enhancing immune activity against cancer cells. The blog highlights their potential in medical applications, emphasizing ongoing research into their therapeutic uses.

Read about the benefit of LL-37 & Thymosin Stack

Scientific Research:

[1] Daniela Xhindoli, Sabrina Pacor, Monica Benincasa, Marco Scocchi, Renato Gennaro, Alessandro Tossi, The human cathelicidin LL-37 — A pore-forming antibacterial peptide and host-cell modulator, Biochimica et Biophysica Acta (BBA) – Biomembranes, Volume 1858, Issue 3,
2016, Pages 546-566.

[2] Ridyard KE, Overhage J. The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent. Antibiotics (Basel). 2021 May 29;10(6):650.

[3] Hiromi Sato, Jimmy B. Feix, Peptide–membrane interactions and mechanisms of membrane destruction by amphipathic α-helical antimicrobial peptides, Biochimica et Biophysica Acta (BBA) – Biomembranes,
Volume 1758, Issue 9, 2006, Pages 1245-1256.

[4] Yang B, Good D, Mosaiab T, Liu W, Ni G, Kaur J, Liu X, Jessop C, Yang L, Fadhil R, Yi Z, Wei MQ. Significance of LL-37 on Immunomodulation and Disease Outcome. Biomed Res Int. 2020 May 16;2020:8349712.

[5] Ramos R, Silva JP, Rodrigues AC, Costa R, Guardão L, Schmitt F, Soares R, Vilanova M, Domingues L, Gama M. Wound healing activity of the human antimicrobial peptide LL37. Peptides. 2011 Jul;32(7):1469-76.

[6] Kahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013 Nov 15;191(10):4895-901.

[7] Lu F, Zhu Y, Zhang G, Liu Z. Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy. Front Pharmacol. 2022 Aug 23;13:944147.

[8] Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012 May;24(2):126-35.

[9] Yang YM, Guo YF, Zhang HS, Sun TY. Antimicrobial peptide LL-37 circulating levels in chronic obstructive pulmonary disease patients with high risk of frequent exacerbations. J Thorac Dis. 2015 Apr;7(4):740-5.

[10] Cirioni O, Giacometti A, Ghiselli R, Bergnach C, Orlando F, Silvestri C, Mocchegiani F, Licci A, Skerlavaj B, Rocchi M, Saba V, Zanetti M, Scalise G. LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother. 2006 May;50(5):1672-9.

Buy LL-37 (CAP-18) New Zealand Today from PharmaGrade.Store

ALL PRODUCT INFORMATION AND ARTICLES ON THIS SITE ARE FOR EDUCATIONAL PURPOSES ONLY

DISCLAIMER: All products sold by PharmaGrade.Store are for research and laboratory use only. These products are not designed for use or consumption by humans or animals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such. By purchasing from our Website the buyer accepts and acknowledges the risks involved with handling of these products. All articles and product information provided on this Website are for informational and educational purposes only. Handling and use of these products should be restricted to suitably qualified professionals